Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Rhea-AI Summary

Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, from 2:00 to 2:30 p.m. ET. Investors are invited to join via webcast. Gain Therapeutics specializes in drug discovery using its proprietary computational platform, SEE-Tx®, targeting allosteric regulators for various diseases. The company’s lead program focuses on Parkinson’s disease, supported by funding from notable organizations.

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, today announced that Chief Executive Officer Eric Richman will participate in a fireside chat during the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference, and invites investors to participate via webcast. Please see additional details below:

B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Format: Fireside Chat
Date: Thursday, April 28, 2022
Time: 2:00 p.m. to 2:30 p.m. ET
Webcast: Registration link

A live webcast of the virtual presentation can be accessed through the Events section of the Company’s website at https://www.gaintherapeutics.com/investors-media/overview.html. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform SEE-Tx®. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas provides opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition and allosteric activation. Gain’s pipeline spans neurodegenerative diseases, lysosomal storage disorders, metabolic diseases and oncology. Gain’s lead program in Parkinson’s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. For more information, please visit https://www.gaintherapeutics.com.

Investor & Media Contacts:

Gain Therapeutics Investor Contact:
Noor Pahlavi
Argot Partners
(212) 600-1902
Gain@argotpartners.com

Gain Therapeutics Media Contact:
Joleen Schultz
Joleen Schultz & Associates
+1 760-271-8150
joleen@joleenschultzassociates.com

 

FAQ

When is the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference featuring Gain Therapeutics?

The conference will take place on April 28, 2022, from 2:00 to 2:30 p.m. ET.

Who will represent Gain Therapeutics at the B. Riley Conference?

CEO Eric Richman will participate in the fireside chat.

How can investors access the Gain Therapeutics webcast?

Investors can access the webcast via the registration link provided in the press release.

What is Gain Therapeutics' focus in drug discovery?

Gain Therapeutics focuses on structurally targeted allosteric regulators for various diseases using its SEE-Tx® platform.

What is Gain Therapeutics' lead program about?

The lead program targets Parkinson's disease and has received funding support from The Michael J. Fox Foundation and others.